Latest Insider Transactions at Ptc Therapeutics, Inc. (PTCT)
This section provides a real-time view of insider transactions for Ptc Therapeutics, Inc. (PTCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PTC THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PTC THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
10,308
-2.11%
|
$546,324
$53.5 P/Share
|
|
Dec 03
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,308
+3.29%
|
$340,164
$33.02 P/Share
|
|
Dec 02
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
85,600
-24.8%
|
$4,451,200
$52.21 P/Share
|
|
Dec 02
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
85,600
+17.12%
|
$4,365,600
$51.0 P/Share
|
|
Dec 02
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
17,800
-7.19%
|
$907,800
$51.89 P/Share
|
|
Dec 02
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
17,800
+11.63%
|
$907,800
$51.0 P/Share
|
|
Dec 02
2024
|
Jerome B Zeldis |
SELL
Open market or private sale
|
Direct |
24,000
-21.13%
|
$1,224,000
$51.64 P/Share
|
|
Dec 02
2024
|
Jerome B Zeldis |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+31.17%
|
$960,000
$40.93 P/Share
|
|
Dec 02
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
2,060
-16.29%
|
$107,120
$52.3 P/Share
|
|
Dec 02
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,060
+23.69%
|
$105,060
$51.0 P/Share
|
|
Dec 02
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
69,550
-12.53%
|
$3,616,600
$52.32 P/Share
|
|
Dec 02
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
69,550
+16.63%
|
$3,547,050
$51.0 P/Share
|
|
Jul 16
2024
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,269
-4.07%
|
$77,146
$34.02 P/Share
|
|
May 22
2024
|
Jerome B Zeldis |
SELL
Open market or private sale
|
Direct |
20,000
-57.97%
|
$760,000
$38.24 P/Share
|
|
May 22
2024
|
Jerome B Zeldis |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+36.7%
|
$520,000
$26.42 P/Share
|
|
May 08
2024
|
David P Southwell |
SELL
Bona fide gift
|
Direct |
1,650
-11.38%
|
-
|
|
May 07
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
175
-0.29%
|
$5,600
$32.82 P/Share
|
|
Apr 19
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,361
-1.47%
|
$80,664
$24.89 P/Share
|
|
Apr 17
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,307
-0.57%
|
$32,675
$25.14 P/Share
|
|
Apr 17
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
787
-1.15%
|
$19,675
$25.14 P/Share
|
|
Apr 02
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
526
-0.87%
|
$14,728
$28.37 P/Share
|
|
Feb 15
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+14.1%
|
-
|
|
Feb 15
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
870
+15.98%
|
-
|
|
Feb 15
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+12.83%
|
-
|
|
Feb 15
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,900
+13.64%
|
-
|
|
Feb 15
2024
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+6.09%
|
-
|
|
Feb 15
2024
|
David P Southwell |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
William F. Bell Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+27.91%
|
-
|
|
Feb 15
2024
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+28.85%
|
-
|
|
Feb 15
2024
|
Mary L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+22.46%
|
-
|
|
Feb 15
2024
|
Glenn Jr Md Phd Steele |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
Alethia Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+23.44%
|
-
|
|
Feb 15
2024
|
Jerome B Zeldis |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+19.66%
|
-
|
|
Feb 15
2024
|
Emma Reeve |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+26.32%
|
-
|
|
Feb 15
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
21,200
+10.07%
|
-
|
|
Feb 15
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+23.3%
|
-
|
|
Feb 15
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,600
+14.89%
|
-
|
|
Feb 15
2024
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,100
+15.88%
|
-
|
|
Jan 30
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
318
-0.89%
|
$8,586
$27.25 P/Share
|
|
Jan 30
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
366
-0.82%
|
$9,882
$27.25 P/Share
|
|
Jan 30
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
794
-1.1%
|
$21,438
$27.25 P/Share
|
|
Jan 30
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
28
-0.75%
|
$756
$27.25 P/Share
|
|
Jan 30
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
618
-1.0%
|
$16,686
$27.25 P/Share
|
|
Jan 22
2024
|
Allan Steven Jacobson |
SELL
Open market or private sale
|
Direct |
10,000
-44.75%
|
$270,000
$27.38 P/Share
|
|
Jan 22
2024
|
Allan Steven Jacobson |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.91%
|
$270,000
$27.05 P/Share
|
|
Jan 09
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,653
-4.41%
|
$47,937
$29.01 P/Share
|
|
Jan 09
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,938
-2.62%
|
$56,202
$29.01 P/Share
|
|
Jan 09
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,225
-3.13%
|
$35,525
$29.01 P/Share
|
|
Jan 09
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,443
-3.28%
|
$157,847
$29.01 P/Share
|